leadf
logo-loader
viewBristol-Myers Squibb Co

Bristol-Myers announces results for Opdivo

Bristol-Myers Squibb Company on Tuesday announced updated results for Opdivo monotherapy

6862528879_c9e63bfaa0_o_opt_opt-(1).jpg
Updated results for Opdivo monotherapy

Bristol-Myers Squibb Company (NYSE:BMY) on Tuesday announced updated results for Opdivo monotherapy.

The pharma said that Opdivo monotherapy (3 mg/kg every two weeks [n=98]) and in combination with Yervoy (Opdivo 1 mg/kg plus Yervoy 3 mg/kg every three weeks [n=61]) in previously treated small cell lung cancer (SCLC) patients, a cohort of the Phase 1/2 open-label CheckMate -032 trial.

The confirmed objective response rate (primary objective) was 25% (95% CI: 15, 37) in patients who received Opdivo plus Yervoy and was 11% (95% CI: 6, 19) with Opdivo alone with additional follow-up.

Response was observed regardless of platinum sensitivity or prior lines of therapy. With the combination, three patients experienced a complete response.

The estimated two-year overall survival rate (secondary objective) was 30% with Opdivo plus Yervoy and was 17% with Opdivo alone. In this updated analysis, no new safety signals were observed. Grade 3/4 treatment-related discontinuation rates were 10% in the Opdivo plus Yervoy group and 4% in the Opdivo group.

Bristol-Myers shares closed up 0.9% at $56.03 on Tuesday.

Quick facts: Bristol-Myers Squibb Co

Price: 59.49 USD

NYSE:BMY
Market: NYSE
Market Cap: $134.09 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Cabral Gold adds 2nd drill rig as company identifies new high-grade veins

Cabral Gold (CVE: CBR-OTC: CBGZF) CEO Alan Carter joined Steve Darling from Proactive Vancouver with news the company has identified at least six new NE trending high-grade veins in the Machichie SW area located immediately north of the MG deposit. Carter telling Proactive what had led them...

2 days, 5 hours ago

2 min read